Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell TAK and other ETFs, options, and stocks.

About TAK

Takeda Pharmaceutical Co., Ltd. engages in the research and development, manufacture, import and export sale, and marketing of pharmaceutical drugs. It operates through the following business divisions: Gastrointestinal Diseases, Rare Diseases, Plasma-Derived Therapies, Oncology, Vaccines, and Neuroscience The company was founded by Takeda Chobei on June 12, 1781 and is headquartered in Osaka, Japan.

CEO

Julie So-Young Kim

CEOJulie So-Young Kim

Employees

47,029

Employees47,029

Headquarters

Osaka, Osaka

HeadquartersOsaka, Osaka

Founded

1781

Founded1781

Employees

47,029

Employees47,029

TAK Key Statistics

Market cap

69.41B

Market cap69.41B

Price-Earnings ratio

285.41

Price-Earnings ratio285.41

Dividend yield

2.75%

Dividend yield2.75%

Average volume

3.00M

Average volume3.00M

High today

$21.66

High today$21.66

Low today

$21.32

Low today$21.32

Open price

$21.46

Open price$21.46

Volume

3.73M

Volume3.73M

52 Week high

$21.73

52 Week high$21.73

52 Week low

$13.91

52 Week low$13.91

TAK News

TipRanks 2d

Takeda Updates Real-World Crohn’s Disease Study as Investors Watch Darvadstrocel Data

Takeda Pharmaceutical Company (TAK) announced an update on their ongoing clinical study. Study Overview: Takeda’s NCT05113095 study, officially titled “Postmar...

TipRanks 2d

Takeda Updates Real-World Study of Maribavir in Transplant Patients

Takeda Pharmaceutical Company (TAK) announced an update on their ongoing clinical study. Study Overview: Takeda’s MARIBEL study, officially titled “Prospective...

TipRanks 2d

Takeda Updates Real-World TAKHZYRO Study in Hereditary Angioedema

Takeda Pharmaceutical Company (TAK) announced an update on their ongoing clinical study. Study Overview: Takeda’s study, titled “Specific Use-Results Survey of...

Analyst ratings

59%

of 17 ratings

Buy

58.8%

Hold

35.3%

Sell

5.9%

More TAK News

TipRanks 2d

Alkermes position intact after Takeda drug pricing, says Needham

Needham keeps a Buy rating on Alkermes (ALKS) after Takeda (TAK) announced the U.S. launch of Orzeyful with a flat list price of $16,500 per 60 tablets, across...

Seeking Alpha 2d

Takeda launches new narcolepsy pill as DEA completes scheduling

Takeda (TAK) on Thursday announced the U.S. launch of its new narcolepsy pill, Orzeyful, which is designed to address the underlying cause of the sleeping disor...

TipRanks 2d

Takeda announces Orzeyful CIV is now available in U.S.

Takeda (TAK) announced that Orzeyful CIV is now available in the U.S. by prescription for the treatment of narcolepsy type 1 in adults, bringing the first and o...

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.